Jennison Associates
TRML

Jennison Associates’s Tourmaline Bio TRML Stock Holding History

Jennison Associates’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-118,487
Closed -$1.8M – 633
2025
Q1 		$1.8M Sell
118,487
-727,313
-86% -$11.7M ﹤0.01% 443
2024
Q4 		$17.2M Sell
845,800
-306,173
-27% -$7.71M 0.01% 357
2024
Q3 		$29.6M Buy
1,151,973
+24,282
+2% +$405K 0.02% 302
2024
Q2 		$14.5M Buy
1,127,691
+12,440
+1% +$200K 0.01% 355
2024
Q1 		$25.5M Buy
+1,115,251
New +$39.3M 0.02% 318

Other funds holding TRML

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Jennison Associates's TRML Position: Q2 2025 in Review

Jennison Associates sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 118,487 shares — an estimated $1.8M sold.

Jennison Associates first reported a position in TRML in Q1 2024 and held it in 5 quarters. The position peaked at $29.6M in Q3 2024. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Jennison Associates reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 118,487 Tourmaline Bio shares in Q2 2025, an estimated $1.8M.
  • Jennison Associates first reported a position in Tourmaline Bio in Q1 2024 and held it in 5 quarters.
  • Jennison Associates's Tourmaline Bio position peaked at $29.6M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.